Acute and long-term effects of nateglinide on insulin secretory pathways

British Journal of Pharmacology

Volumn 142, Issue 2, 2004, Pages 367-373

  Ball, Andrew J ^a,b   Flatt, Peter R ^a   McClenaghan, Neville H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clonal pancreatic beta cells; Efaroxan; Glibenclamide; Insulin release; Nateglinide; Tolbutamide

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE; EFAROXAN; FORSKOLIN; GLIBENCLAMIDE; GLUCOSE; INSULIN; LEUCINE; NATEGLINIDE; PHORBOL 13 ACETATE 12 MYRISTATE; POTASSIUM CHANNEL; TOLBUTAMIDE;

ANIMAL CELL; ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; EVOKED RESPONSE; INHIBITION KINETICS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; STIMULATION; TIME;

ANIMALS; CATTLE; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; INSULIN; PHENYLALANINE; RATS; TIME FACTORS;

EID: 2942520864     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705766     Document Type: Article

References (51)

1. AGUILAR-BRYAN, L., CLEMENT, J.P., GONZALEZ, G., KUNJILWAR, K., BABENKO, A. & BRYAN, J. (1998). Toward understanding the assembly and structure of KATP channels. Physiol. Rev., 78, 227-245.
2. AGUILAR-BRYAN, L., NICHOLS, G.G., WECHSLER, S.W., CLEMENT, J.P., BOYD, A.E., GONZÁLEZ, G., HERRERA-SOSA, H., NGUY, K., BRYAN, J. & NELSON, D.A. (1995). Cloning of the β-cell high-affinity sulphonylurea receptor: a regulator of insulin secretion. Science, 268, 423-425.
3. + channels and insulin secretion: their role in health and disease. Diabetologia, 42, 903-919.
4. BALL, A.J., FLATT, P.R. & MCCLENAGHAN, N.H. (2000a). Desensitization of sulphonylurea-and nutrient-induced insulin secretion following prolonged treatment with glibenclamide. Em. J. Pharmacol., 408, 327-333.
5. BALL, A.J., FLATT, P.R. & MCCLENAGHAN, N.H. (2000b). Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14R and RX801080. Pharmacol. Res., 42, 575-579.
6. BALL, A.J., MCCLUSKEY, J.T., FLATT, P.R. & MCCLENAGHAN, N.H. (2000c). Drug-induced desensitization of insulinotropic actions of sulfonylureas. Biochem. Biophys. Res. Commun., 271, 234-239.
7. BOKVIST, K., HOY, M., BUSCHARD, K., HOLST, J.J., THOMSEN, M.K. & GROMADA, J. (1999). Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells. Eur. J. Pharmacol, 386, 105-111.
8. ATP-channel independent secretion in rat pancreatic α- and β-cells. Diabetologia, 41, A139.
9. BRATANOVA-TOCHKOVA, T.K., CHENG, H., DANIEL, S., GUNAWARDANA, S., LIU, Y.J., MULVANEY-MUSA, J., SCHERMERHORN, T., STRAUB, S.G., YAJIMA, H. & SHARP, G.W. (2002). Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes, 51, S83-S90.
10. CHAPMAN, J.C., MCCLENAGHAN, N.H., COSGROVE, K.E., HASHMI, M.N., SHEPHERD, R.M., GIESBERTS, A.N., WHITE, S.J., AMMALA, C., FLATT, P.R. & DUNNE, M.J. (1999). ATP-sensitive potassium channels and efaroxan-induced insulin release in the electrofusion-derived BRIN-BD11 beta-cell line. Diabetes, 48, 2349-2357.
11. DEFRONZO, R.A. (ed) (1998). Current Therapy of Diabetes Mellitus. St Louis: Mosby.
12. DORNHORST, A. (2001). Insulinotropic meglitinide analogues. Lancet, 358, 1709-1716.
13. ELIASSON, L., RENSTRÖM, E., ÄMMÄLÄ, C., BERGGREN, P.-O., BERTORELLO, A.M., BOKVIST, K., CHIBALIN, A., DEENEY, J.T., FLATT, P.R., GÄBEL, J., GROMADA, J., LARSSON, O., LINDSTRÖM, P., RHODES, CJ & RORSMAN, P. (1996). PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic β-cells. Science, 271, 813-815.
14. FLATT, P.R. & BAILEY, C.J. (1981). Abnormal plasma glucose and insulin responses in heterozygous (ob/+) mice. Diabetologia, 20, 573-577.
15. FLATT, P.R., SHIBIER, O., SZECOWKA, J. & BERGGREN, P.-O. (1994). New perspectives on the actions of sulphonylureas and hyperglycamic sulphonamides on the pancreatic B-cell. Diab. Metabol., 20, 157-162.
16. + channels in mouse B cells. J. Clin. Invest., 89, 1288-1295.
17. CRIBBLE, F.M., MANLEY, S.E. & LEVY, J.C. (2001). Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care, 24, 1221-1225.
18. GROMADA, J., BOKVIST, K., HOY, M., OLSEN, H.L., LINDSTROM, P., HANSEN, B.S., GOTFREDSEN, C.F., RORSMAN, P. & THOMSEN, M.K. (2002). Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis. Eur. J. Endocrinol, 147, 133-142.
19. GRUNBERGER, G. (1993). Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus. Drug. Saf., 9, 249-253.
20. HANEFELD, M., BOUTER, K.P., DICKINSON, S. & GUITARD, C. (2000). Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diab. Care, 23, 202-207.
21. HANSEN, A.M., CHRISTENSEN, I.T., HANSEN, J.B., CARR, R.D., ASHCROFT, P.M. & WAHL, P. (2002). Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes, 51, 2789-2795.
22. HOLLANDER, P.A., SCHWARTZ, S.L., GATLIN, M.R., HAAS, S.J., ZHENG, H., FOLEY, J.E. & DUNNING, B.E. (2001). Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diab. Care, 24, 983-988.
23. HORTON, E.S., CLINKINGBEARD, C., GATLIN, M., FOLEY, J., MALLOWS, S. & SHEN, S. (2000). Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care, 23, 1660-1665.
24. HU, S. (2002). Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. Eur. J. Pharmacol., 442, 163-171.
25. HU, S., BOETTCHER, B.R. & DUNNING, B.E. (2003). The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia, 46, M37-M43.
26. HU, S., WANG, S. & DUNNING, B.E. (2001). Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int. J. Exp. Diabetes Res., 2, 63-72.
27. HU, S., WANG, S., FANELLI, B., BELL, P.A., DUNNING, B.E., GEISSE, S., SCHMITZ, R. & BOETTCHER, B.R. (2000). Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J. Pharmacol. Exp. Ther., 293, 444-452.
28. + channel. FEBS Lett., 409, 715-720.
29. KALBAG, J.B., WALTER, Y.H., NEDELMAN, J.R. & MCLEOD, J.F. (2001). Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diab. Care, 24, 73-77.
30. + channel activity. Diabetes, 48, 2001-2006.
31. KEILSON, L., MATHER, S., WALTER, Y.H., SUBRAMANIAN, S. & MCLEOD, J.F. (2000). Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J. Clin. Endocrinol Metab., 85, 1081-1086.
32. LAGHMICH, A., LADRIERE, L., MALAISSE-LAGAE, F. & MALAISSE, W.J. (1999). Long-term effects of glibenelamide and nateglinide upon pancreatic islet function in normal and diabetic rats. Pharmacol. Res., 40, 475-482.
33. MARRE, M., VAN GAAL, L., USADEL, K.H., BALL, M., WHATMOUGH, I. & GUITARD, C. (2002). Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diab. Obes. Metab., 4, 177-186.
34. MATTHEWS, D.R., CULL, C.A., STRATTON, I.M., HOLMAN, R.R. & TURNER, R.C. (1998). UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diab. Med., 15, 297-303.
35. MCCLENAGHAN, N.H., BALL, A.J. & FLATT, P.R. (2000). Induced desensitization of the insulinotropic effects of antidiabetic drugs, BTS 67 582 and tolbutamide. Br. J. Pharmacol, 130, 478-484.
36. MCCLENAGHAN, N.H., BALL, A.J. & FLATT, P.R. (2001). Specific desensitization of sulfonylurea- but not imidazoline-induced insulin release after prolonged tolbutamide exposure. Biochem. Pharmacol., 61, 527-536.
37. MCCLENAGHAN, N.H., BARNETT, C.R., AH-SING, E., ABDEL-WAHAB, Y.H.A., O'HARTE, F.P.M., YOON, T.-W., SWANSTON-FLATT, S.K. & FLATT, P.R. (1996). Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes, 45, 1132-1140.
38. MCCLENAGHAN, N.H. & FLATT, P.R. (1999a). Physiological and pharmalogical regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diab. Obes. Metab, 1, 1-14.
39. MCCLENAGHAN, N.H. & FLATT, P.R. (1999b). Engineering cultured insulin-secreting pancreatic B-cell lines. J. Mol. Med., 77, 235-243.
40. NIEMI, M., BACKMAN, J.T., NEUVONEN, M. & NEUVONEN, P.J. (2003). Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. Br. J. Clin. Pharmacol., 56, 427-432.
41. PRATLEY, R.E. & WEYER, C. (2001). The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia, 44, 929-945.
42. ATP channels is mediated by Kir6.2. Proc. Natl. Acad. Sci. U.S.A., 94, 11716-11720.
43. RABUAZZO, A.M., BUSCEMA, M., VINCI, C., CALTABIANO, V., VETRI, M., FORTE, F., VIGNERI, R. & PURRELLO, F. (1992). Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms. Endocrinology, 131, 1815-1820.
44. RENSTRÖM, E., BARG, S., THEVENOD, F. & RORSMAN, P. (2002). Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K(+) channel-independent action. Diabetes, 51, S33-S36.
45. ROSENSTOCK, J., SHEN, S.G., GATLIN, M.R. & FOLEY, J.E. (2002). Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diab. Care, 25, 1529-1533.
46. SALGADO, A.P., SANTOS, R.M., FERNANDES, A.P., TOME, A.R., FLATT, P.R. & ROSARIO, L.M. (2000). Glucose-mediated Ca(2+) signalling in single clonal insulin-secreting cells: evidence for a mixed model of cellular activation. Int. J. Blochem. Cell Biol., 32, 557-569.
47. STRAUB, S.G. & SHARP, G.W. (2002). Glucose-stimulated signaling pathways in biphasic insulin secretion. Diab. Metab. Res. Rev., 18, 451-463.
48. SUNAGA, Y., GONOI, T., SHIBASAKI, T., ICHIKAWA, K., KUSAMA, H., YANO, H. & SEINO, S. (2001). The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K + channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur. J. Pharmacol., 431, 119-125.
49. TIAN, Y.-M., JOHNSON, G. & ASHCROFT, S.J.H. (1998). Sulfonylureas stimulate exoxytosis from pancreatic β-cells by a mechanism that does not involve direct activation of protein kinase C. Diabetes, 47, 1722-1726.
50. UTO, Y., TENO, S., IWAMOTO, Y., OMORI, Y. & TAKIZAWA, T. (2002). Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion. Metabolism, 51, 20-24.
51. YADA, T. (1994). Action mechanisms of amino acids in pancreatic B-cells. In: Frontiers of Insulin Secretion and Pancreatic B-Cell Research, ed. Flatt, P.R. & Lenzen, S. pp. 129-135. London: Smith-Gordon.